Uma oportunidade para resgatar o valor da terapia hormonal no climatério A agência Food and Drug Administration (FDA) removeu o alerta de “tarja preta” dos produtos utilizados na terapia hormonal

Key Points

• The aim is to discuss the history and recent changes regarding hormone therapy for menopausal women.
• Analysis of historical perspectives on hormone therapy.
• Review of FDA's decision regarding black box warnings.
• Discussion of implications for clinical practice.
• Historical condemnation of hormone therapy is viewed as a major medical error.
• Removal of the black box warning may restore confidence in hormone therapy.
• Increased awareness may lead to a shift in treatment approaches for menopausal women.